A vaccine against nicotine for smoking cessation: a randomized controlled trial.

ABSTRACT:

Background

Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period.

Methodology/principal findings

229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a stat

SUBMITTER: Cornuz J 

PROVIDER: S-EPMC2432028 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature